Please login to the form below

Not currently logged in
Email:
Password:

haemophilia B

This page shows the latest haemophilia B news and features for those working in and with pharma, biotech and healthcare.

Sanofi narrows focus, shedding diabetes and cardiovascular research

Sanofi narrows focus, shedding diabetes and cardiovascular research

This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)

Latest news

  • Sobi set to spend up to $915m to acquire Dova Pharmaceuticals Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

    Guido Oelkers. Sobi’s  haematology franchise  includes Elocta, a recombinant clotting factor VIII therapy for haemophilia A that offers an extended half-life, and Alprolix, a long-lasting recombinant factor IX ... Fc fusion protein for haemophilia B.

  • Pfizer goes big on gene therapy with $500m facility spend Pfizer goes big on gene therapy with $500m facility spend

    That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage  haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a  ... haemophilia A candidate that recently reported encouraging phase

  • ACPs to lead gene therapies in haemophilia market growth ACPs to lead gene therapies in haemophilia market growth

    GlobalData predicts the wave of novel treatments for haemophilia A and haemophilia B market will see the market grow from $6.93bn in 2018 to $9.29bn in 2028. ... for haemophilia B, are leading the clinical development race for gene therapies.

  • New results back Sangamo, UniQure haemophilia gene therapies New results back Sangamo, UniQure haemophilia gene therapies

    Haemophilia B. Meanwhile, Dutch biotech UniQure presented updated results at ISTH on three haemophilia B patients treated in its phase 2b study of AMT-061, a gene therapy that aims to ... After 36 weeks, Factor IX activity was at an average of 45% of

  • Brexit Brexit "having impact on EU drug development”

    That has already affected a planned update of the EMA’s guidelines on the development of new medicines to treat haemophilia A and B, where there are a number of new

More from news
Approximately 5 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... Portfolio/pipeline in haemophilia and other rare

  • Deal Watch August 2016 Deal Watch August 2016

    premiums. One commentator suggested BioMarin could be a Plan B for Sanofi. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for

  • Deal Watch February 2016 Deal Watch February 2016

    of haemophilia A and B.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Exercise of opt-out/ termination. 945. Macrogenics / J&J. MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical). ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics